Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 1Peripheral Nervous System Diseases 1Head and Neck Neoplasms 1HER2-positive Breast Cancer 1Brain Neoplasms 1

Interventions

Trastuzumab 19pyrotinib 14pertuzumab 8Docetaxel 7Paclitaxel 6Capecitabine 4Carboplatin 3neratinib 2Protons 2Neoadjuvant Therapy 2Fulvestrant 2Ado-Trastuzumab Emtansine 2tucatinib 1trastuzumab deruxtecan 1pegfilgrastim 1palbociclib 1inavolisib 1exemestane 1envafolimab 1dalpiciclib 1atezolizumab 1Taxoids 1Metformin 1Leuprolide 1Letrozole 1Isovaleryl-CoA Dehydrogenase 1Goserelin 1Genetic Testing 1Fluorodeoxyglucose F18 1Enfuvirtide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × HER2-positive Breast Cancer × Taxoids × Clear all
NCT06217185 2024-02-28

The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).

Hebei Medical University Fourth Hospital

Phase 4 Recruiting
100 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡